tbuckley/cabot-search huggingface dataset:
Randomized Controlled Trial of Mobile Closed-Loop Control
Authors: Boris Kovatchev, Stacey M. Anderson, Dan Raghinaru, Yogish C. Kudva, Lori M. Laffel, Carol Levy, Jordan E. Pinsker, R. Paul Wadwa, Bruce Buckingham, Francis J. Doyle, Sue A. Brown, Mei Mei Church, Vikash Dadlani, Eyal Dassau, Laya Ekhlaspour, Gregory P. Forlenza, Elvira Isganaitis, David W. Lam, John Lum, Roy W. Beck, Boris Kovatchev, Stacey M. Anderson, Sue A. Brown, Emma Emory, Mary Voelmle, Katie Conshafter, Kim Morris, Mary Oliveri, Harry Mitchell, Kayla Calvo, Christian Wakeman, Marc Breton, Lori M. Laffel, Elvira Isganaitis, Louise Ambler-Osborn, Emily Flint, Alan Schultz, Kenny Kim, Jordan E. Pinsker, Mei Mei Church, Camille Andre, Carol Levy, David W. Lam, Grenye O’Malley, Camilla Levister, Selassie Ogyaadu, Yogish C. Kudva, Vikash Dadlani, Vinaya Simha, Shelly McCrady-Spitzer, Corey Reid, R. Paul Wadwa, Gregory P. Forlenza, Emily Jost, Laurel Messer, Cari Berget, Lindsey Towers, Bruce Buckingham, Laya Ekhlaspour, Liana Hsu, Sarah Loebner, Francis J. Doyle, Eyal Dassau, John Lum, Roy W. Beck, Tiffany Campos, Samantha Passman, Carlos Murphy, Nandan Patibandla, Dan Raghinaru, Craig Kollman
Journal: Diabetes Care (2020)

OBJECTIVE Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c &amp;lt;10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P &amp;lt; 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P &amp;lt; 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
Diastolic Blood Pressure and Heart Rate Are Independently Associated With Mortality in Chronic Aortic Regurgitation
Authors: Li-Tan Yang, Patricia A. Pellikka, Maurice Enriquez-Sarano, Christopher G. Scott, Ratnasari Padang, Sunil V. Mankad, Hartzell V. Schaff, Hector I. Michelena
Journal: Journal of the American College of Cardiology (2020)
Anemia Point Prevalence in Patients Receiving Chemotherapy in 56 Centers in Italy and Austria
Authors: L. Merlini, G. Carteni, S. Iacobelli, C. Stelitano, M. Airoldi, P. Balke, F. Keil, F. Haslbauer, L. Belton, B. Pujol
Journal: Annals of Oncology (2012)
P-0256 Phase II Study to Evaluate Efficacy and Safety of Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer (MCRC) Patients
Authors: Pilar García Alfonso, Manuel Chaves, Andrés Muñoz, Antonieta Salud, Carlos García-Girón, Cristina Grávalos, Bartomeu Massutí, Encarnación González-Flores, Bernardo Queralt, Amelia López-Ladrón, Ferrán Losa, Amparo Oltra, Ma José Gómez, J. Manuel Campos, Enrique Aranda
Journal: Annals of Oncology (2012)
Best Practices in Assessing Aging Physicians for Professional Competency
Authors: Jeffrey L. Saver
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A patient‐oriented, general‐practitioner‐level, deep‐learning‐based cutaneous pigmented lesion risk classifier on a smartphone
Authors: Y.P.H. Chin, Z.Y. Hou, M.Y. Lee, H.M. Chu, H.H. Wang, Y.T. Lin, A. Gittin, S.C. Chien, P.A. Nguyen, L.C. Li, T.H. Chang, Y.C.J. Li
Journal: British Journal of Dermatology (2020)
Travel-associated chikungunya acquired in Myanmar in 2019
Authors: Marta Díaz-Menéndez, Elena Trigo Esteban, Mugen Ujiie, Guido Calleri, Camilla Rothe, Denis Malvy, Emanuele Nicastri, Alfred L Bissinger, Marc Grandadam, Jonathan D Alpern, Federico Gobbi, Patricia Schlagenhauf, Alexandre Duvignaud, Emilie Javelle, Takato Nakamoto, Spinello Antinori, Davidson H Hamer
Journal: Eurosurveillance (2020)

Eighteen cases of chikungunya virus infection in travellers returning from Myanmar were reported to the GeoSentinel Surveillance Network, its subnetwork EuroTravNet and TropNet in 2019, reflecting an ongoing local outbreak. This report reinforces the importance of travellers as sentinels of emerging arboviral outbreaks and highlights the importance of vigilance for imported cases, due to the potential for dissemination of the virus into areas with competent local vectors and conducive environmental conditions.
Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database
Authors: M.E. Salem, J. Yin, R.M. Goldberg, L.D. Pederson, N. Wolmark, S.R. Alberts, J. Taieb, J.L. Marshall, S. Lonardi, T. Yoshino, R.S. Kerr, G. Yothers, A. Grothey, T. Andre, A. De Gramont, Q. Shi
Journal: Annals of Oncology (2020)
PD-0012 Metabolic Syndrome, Alcohol Intake and Colorectal Cancer: Data from a Greek Case Control Study
Authors: Niki Kontou, Theodora Psaltopoulou, Nick Soupos, Evangelos Polychronopoulos, Dimitrios Xinopoulos, Athena Linos, Meletios Dimopoulos, Demosthenes Panagiotakos
Journal: Annals of Oncology (2012)
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
Authors: James Chih-Hsin Yang, Martin Schuler, Sanjay Popat, Satoru Miura, Simon Heeke, Keunchil Park, Angela Märten, Edward S. Kim
Journal: Journal of Thoracic Oncology (2020)

Limited clinical data are available regarding the efficacy of EGFR tyrosine kinase inhibitors (EGFR TKIs) in patients with NSCLC harboring uncommon EGFR mutations. This pooled analysis assessed the activity of afatinib in 693 patients with tumors harboring uncommon EGFR mutations treated in randomized clinical trials, compassionate-use and expanded-access programs, phase IIIb trials, noninterventional trials, and case series or studies.Patients had uncommon EGFR mutations, which were categorized as follows: (1) T790M; (2) exon 20 insertions; (3) "major" uncommon mutations (G719X, L861Q, and S768I, with or without any other mutation except T790M or an exon 20 insertion); (4) compound mutations; and (5) other uncommon mutations. Key end points were overall response rate (ORR), duration of response, and time to treatment failure (TTF).In EGFR TKI-naive patients (n = 315), afatinib demonstrated activity against major uncommon mutations (median TTF = 10.8 mo; 95% confidence interval [CI]: 8.1-16.6; ORR = 60.0%), compound mutations (median TTF = 14.7 mo; 95% CI: 6.8-18.5; ORR = 77.1%), other uncommon mutations (median TTF = 4.5 mo; 95% CI: 2.9-9.7; ORR = 65.2%), and some exon 20 insertions (median TTF = 4.2 mo; 95% CI: 2.8-5.3; ORR = 24.3%). The median duration of response for major uncommon mutations, compound mutations, other uncommon mutations, and some exon 20 insertions was 17.1, 16.6, 9.0, and 11.9 months, respectively. Activity of afatinib was also observed in EGFR TKI-pretreated patients (n = 378). A searchable database of these outcomes by individual genotype was generated.Afatinib has clinical activity in NSCLC against major uncommon and compound EGFR mutations. It also has broad activity against other uncommon EGFR mutations and some exon 20 insertions. The data support the use of afatinib in these settings.
Association Between CPG Island Methylator Phenotype (CIMP) and Treatment Response of Folfiri with Cetuximab in Patients with Metastatic Colorectal Cancer (MCRC)
Authors: S.H. Kim, K.H. Park, S.J. Shin, K.Y. Lee, T.I. Kim, N.K. Kim, S.Y. Rha, J.K. Roh, J.B. Ahn
Journal: Annals of Oncology (2012)
Could the Safety Profile of Everolimus be Different in Different Cancers? Fondazione IRCCS Istituto Nazionale Tumori (INT) Experience in Renal Cell Carcinoma, Neuroendocrine Tumors (NETS) and Biliary-Tract Cancers
Authors: E. Verzoni, S. Pusceddu, G. Procopio, R. Buzzoni, I. Testa, E. Bajetta, A. Damato, F.G.M. De Braud
Journal: Annals of Oncology (2012)
Prognostic Factors in Development of Brain Metastasis in Stage III Non-Small Cell Lung Cancer Patients After Definitive Treatment
Authors: I. Alsan Cetin, Z. Akgün Cetinkaya, P.F. Yumuk, F. Dane, G. Karaüç, N. Sunnetci, N.S. Turhal, B.M. Atasoy
Journal: Annals of Oncology (2012)
Two Distinct AXES Identified by Gene Expression Profiles Correlate with Biological Features and Clinical Outcome in Colorectal Cancer
Authors: M. Inoue, S. Takahashi, H. Soeda, H. Shimodaira, M. Watanabe, K. Miura, I. Sasaki, S. Kato, C. Ishioka
Journal: Annals of Oncology (2012)
Characterization of diversity of measles viruses in India: Genomic sequencing and comparative genomics studies
Authors: Sunil R. Vaidya, Sunitha M. Kasibhatla, Divya R. Bhattad, Mukund R. Ramtirthkar, Mohan M. Kale, Chandrashekhar G. Raut, Urmila Kulkarni-Kale
Journal: Journal of Infection (2020)
Cytokeratin 19 Fragment (CYFRA21-1) Predicts the Efficacy of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) in Non-Small-Cell Lung Cancer (NSCLC) Harboring EGFR Mutation
Authors: K. Tanaka, A. Hata, R. Kaji, S. Fujita, J. Takeshita, T. Matsumoto, K. Monden, K. Nagata, S. Nanjo, K. Otsuka, R. Tachikawa, K. Otsuka, M. Hayashi, K. Tomii, N. Katakami
Journal: Annals of Oncology (2012)
Backlash Over Meat Dietary Recommendations Raises Questions About Corporate Ties to Nutrition Scientists
Authors: Rita Rubin
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Physical activity compared to adiposity and risk of liver-related mortality: Results from two prospective, nationwide cohorts
Authors: Tracey G. Simon, Mi Na Kim, Xiao Luo, Wanshui Yang, Yanan Ma, Dawn Q. Chong, Charles S. Fuchs, Jeffrey A. Meyerhardt, Kathleen E. Corey, Raymond T. Chung, Meir Stampfer, Xuehong Zhang, Edward L. Giovannucci, Andrew T. Chan
Journal: Journal of Hepatology (2020)
Fluorescent labeling of major honeybee allergens Api m 1 and Api m 2 with quantum dots and the development of a multiplex basophil activation test
Authors: Ana Koren, Mojca Lunder, Peter Molek, Peter Kopač, Abida Zahirović, Pia Gattinger, Irene Mittermann, Rudolf Valenta, Peter Korošec
Journal: Allergy (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Personalizing Cancer Treatment of Combined Targeting of PI3K/AKT and RAS/MEK Pathways in Advanced Cancer Patients: From the Start Phase I Clinical Trial Program
Authors: T. Shimizu, A. Patnaik, K.P. Papadopoulos, M. Beeram, D. Rasco, L.S. Smith, R.L. Drengler, S. Gunn, L. Smetzer, T. Mays, B. Kaiser, M.J. Wick, A.W. Tolcher
Journal: Annals of Oncology (2012)
mTORC1 directly inhibits AMPK to promote cell proliferation under nutrient stress
Authors: Naomi X. Y. Ling, Adrian Kaczmarek, Ashfaqul Hoque, Elizabeth Davie, Kevin R. W. Ngoei, Kaitlin R. Morrison, William J. Smiles, Gabriella M. Forte, Tingting Wang, Shervi Lie, Toby A. Dite, Christopher G. Langendorf, John W. Scott, Jonathan S. Oakhill, Janni Petersen
Journal: Nature Metabolism (2020)
Essor Study: Oral Chemotherapies for Oncology Practices: a Retrospective Analysis in the Community Setting for Selected Drugs
Authors: F. Grude, J. Douillard, C. El Kouri, P. Donny, M. Urbanski, A. Chaslerie, S. Piau, H. Bourgeois, J. Metges, J. Pivette
Journal: Annals of Oncology (2012)
Retrospective Efficacy and Safety Analysis of Erlotinib (E), Pemetrexed (P) and Docetaxel (D) in Previously Treated Non-Small-Cell Lung Cancer Patients (NSCLC) without EGFR Mutation
Authors: J. Takeshita, N. Katakami, A. Nishiyama, H. Yoshioka, M. Iwasaku, A. Hata, F. Imamura, K. Nishino, S. Yokota, S. Morita
Journal: Annals of Oncology (2012)
A Man in His 40s With Coronary-to-Pulmonary Artery Collateralizations
Authors: Hourmazd Haghbayan, Eric A. Coomes, Keith Gunaratne
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)
Authors: D.R. Camidge, R.C. Doebele, M. Ballas, T. Jahan, M. Haigentz, D. Hoffman, J. Spicer, H. West, S. Yurasov, A.C. Mita
Journal: Annals of Oncology (2012)
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study of Onartuzumab (METMAB) with Either Bevacizumab + Platinum + Paclitaxel or Pemetrexed + Platinum as First-Line Treatment for Patients (PTS) with Stage IIIB or IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Authors: H. Wakelee, W. Yu, K. Rittweger, V.E. Paton
Journal: Annals of Oncology (2012)
Treatments and Outcome of NSCLC Patients who Receive Gefitinib for More than Three Years
Authors: K. Otsuka, N. Katakami, A. Hata, R. Kaji, S. Fujita, K. Nagata, A. Nakagawa, R. Tachikawa, K. Otsuka, K. Tomii
Journal: Annals of Oncology (2012)
Metronomic Oral Cyclophosphamide in the Treatment of Metastatic Soft Tissue Sarcoma: Is there a Role for Maintenance Therapy?
Authors: A.C.R. Ferrari, V.P. Camargo, G.M. Bariani, M.S. Goncalves, P.M. Hoff, G. De Castro
Journal: Annals of Oncology (2012)
Phase I Study of Afatinib (BIBW 2992), An Erbb Family Blocker Plus Nintedanib (BIBF 1120), A Triple Angiokinase Inhibitor, in Patients (PTS) With Advanced Solid Tumours
Authors: J. Soria, A. Hollebecque, C. Massard, E. Deutsch, A. Varga, N. Morsli, M. Ould Kaci, H. Staines, K. Marzin, R. Bahleda
Journal: Annals of Oncology (2012)
Exploratory Analysis of the Relationship Between Her2 Expression (BY QRT-PCR) and Efficacy with First-Line Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (HT) in a Randomized Phase 2 Study of Patients (PTS) with HER2-Positive MBC
Authors: E.A. Perez, S. Hurvitz, L.C. Amler, V. Ng, E. Guardino, L. Gianni
Journal: Annals of Oncology (2012)
RACGAP1 overexpression in uterine carcinosarcomas.
Authors: Shijun Mi, Mingyan Lin, Jennifer Heim, Sara Isani, Jurriaan Brouwer-Visser, Maria Cossio-Poblete, David Smotkin, Marc J. Gunter, Deyou Zheng, Gloria S. Huang
Journal: Journal of Clinical Oncology (2013)

e22009 Background: Uterine carcinosarcomas, also known as malignant mixed mullerian tumors (MMMT), are rare and highly aggressive neoplasms that carry a poor prognosis even when diagnosed at an early stage. A better understanding of the molecular mechanisms underlying the development of uterine carcinosarcoma may lead to specific targeted therapies for these refractory tumors. Methods: Using a next generation sequencing approach and bioinformatic analysis, we compared the whole transcriptomes of 6 histologically normal endometrial tissues and 6 uterine carcinosarcoma tissues from patients. Quantitative real-time PCR and immunoblotting were done to validate the differentially expressed genes. Lentiviral transfection with short hairpin RNAs was performed to achieve targeted gene silencing in a carcinosarcoma cell line. p53 and survivin levels were monitored by immunoblotting. Results: We identified 27 dramatically differentially expressed genes between normal endometrial tissues and uterine carcinosarcoma tissues from patients. We confirmed the differential expression of these genes between normal tissues and uterine carcinosarcoma tissues by qRT-PCR. Of these, we found that RACGAP1 is significantly overexpressed in all of the uterine carcinosarcoma tissues at the mRNA level and at the protein level, compared to normal endometrial tissues. Silencing of RACGAP1 by shRNA in a carcinosarcoma cell line remarkably reduces cancer cell proliferation and leads to p53 upregulation and survivin downregulation. Conclusions: Our data demonstrate that RACGAP1 may represent a novel biomarker and therapeutic target for uterine carcinosarcomas.
High-Dose Vitamin D Supplementation and Bone Health
Authors: Hao Li, Zhou Xu, Ling-quan Kong
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Derivation and Validation of Blood MRNA Expression Signatures to Stratify Castration Resistant Prostate Cancer Patients and Predict Poor Outcome
Authors: D. Olmos Hidalgo, D. Brewer, G. Attard, D. Danila, J. Clark, C. Parker, E. Castro, M. Fleischer, A.H.M. Reid, S. Sandhu, R.J. Jones, C.S. Cooper, H.I. Scher, J.S. De Bono
Journal: Annals of Oncology (2012)
Extended Follow-up From a Randomized Clinical Trial of Routine Amoxicillin in the Treatment of Uncomplicated Severe Acute Malnutrition in Niger
Authors: Sheila Isanaka, Kyra H Grantz, Fatou Berthé, Myrto Schaefer, Eric Adehossi, Rebecca F. Grais
Journal: JAMA Pediatrics (2020)

Extended Follow-up From a Randomized Clinical Trial of Routine Amoxicillin in the Treatment of Uncomplicated Severe Acute Malnutrition in Niger Evidence to support current guidelines recommending routine antibiotic use in the outpatient management of uncomplicated severe acute malnutrition (SAM) is limited and based largely on data from historical inpatient settings. 1The evidence from 2 clinical trials 2,3 on the effect of routine antibiotic use on nutritional recovery differs.In Malawi, where HIV and kwashiorkor prevalence are high, routine antibiotics increased nutritional recovery and decreased mortality. 2In Niger, where HIV and kwashiorkor prevalence are low, we found no benefit of routine amoxicillin on nutritional recovery or mortality, although children receiving amoxicillin had a reduced risk of transfer to inpatient care. 3 Both reports only considered short-term risks and benefits during nutritional treatment (mean [SD] time to recovery, 29 [19] days in Malawi 2 and 29 [13] days in Niger 3 ), although immunodeficiencies and risk of relapse or morbidity associated with SAM may persist beyond nutritional recovery. 4To broaden the available evidence, we present the first analysis (to our knowledge) to assess the outcome of routine antibiotic use in outpatient SAM management, including follow-up during and after nutritional treatment.Methods | A complete description of the trial design, procedures, and outcomes has been published previously. 3 Briefly, children aged 6 to 59 months who presented with SAM in Madarounfa, Niger, between October 2012 and November 2013 were randomly assigned 1:1 to receive amoxicillin (80 mg/kg/d) or a placebo for 7 days.All children received standard care for uncomplicated SAM for a minimum of 3 weeks and a maximum of 8 weeks.Children were followed up weekly for anthropometric, clinical, and vital status during treatment and (as per trial protocol) at 4, 8, and 12 weeks after admission.